Changing the spatial location of electricity generation to increase water availability in areas with drought: a feasibility study and quantification of air quality impacts in Texas

The feasibility, cost, and air quality impacts of using electrical grids to shift water use from drought-stricken regions to areas with more water availability were examined. Power plant cooling represents a large portion of freshwater withdrawals in the United States, and shifting where electricity generation occurs can allow the grid to act as a virtual water pipeline, increasing water availability in regions with drought by reducing water consumption and withdrawals for power generation. During a 2006 drought, shifting electricity generation out of the most impacted areas of South Texas (~10% of base case generation) to other parts of the grid would have been feasible using transmission and power generation available at the time, and some areas would experience changes in air quality. Although expensive, drought-based electricity dispatch is a potential parallel strategy that can be faster to implement than other infrastructure changes, such as air cooling or water pipelines.National Science Foundation (U.S.). Office of Emerging Frontiers in Research and Innovation (Grant 0835414)United States. Dept. of Energ

Electron spin dynamics in quantum dots and related nanostructures due to hyperfine interaction with nuclei

We review and summarize recent theoretical and experimental work on electron spin dynamics in quantum dots and related nanostructures due to hyperfine interaction with surrounding nuclear spins. This topic is of particular interest with respect to several proposals for quantum information processing in solid state systems. Specifically, we investigate the hyperfine interaction of an electron spin confined in a quantum dot in an s-type conduction band with the nuclear spins in the dot. This interaction is proportional to the square modulus of the electron wave function at the location of each nucleus leading to an inhomogeneous coupling, i.e. nuclei in different locations are coupled with different strength. In the case of an initially fully polarized nuclear spin system an exact analytical solution for the spin dynamics can be found. For not completely polarized nuclei, approximation-free results can only be obtained numerically in sufficiently small systems. We compare these exact results with findings from several approximation strategies.Comment: 26 pages, 9 figures. Topical Review to appear in J. Phys.: Condens. Matte

Phonons and related properties of extended systems from density-functional perturbation theory

This article reviews the current status of lattice-dynamical calculations in crystals, using density-functional perturbation theory, with emphasis on the plane-wave pseudo-potential method. Several specialized topics are treated, including the implementation for metals, the calculation of the response to macroscopic electric fields and their relevance to long wave-length vibrations in polar materials, the response to strain deformations, and higher-order responses. The success of this methodology is demonstrated with a number of applications existing in the literature.Comment: 52 pages, 14 figures, submitted to Review of Modern Physic

Interactive effects between nest microclimate and nest vegetation structure confirm microclimate thresholds for Lesser Prairie-Chicken nest survival

Citation: Grisham, B. A., Godar, A. J., Boal, C. W., & Haukos, D. A. (2016). Interactive effects between nest microclimate and nest vegetation structure confirm microclimate thresholds for Lesser Prairie-Chicken nest survival. Condor, 118(4), 728-746. doi:10.1650/CONDOR-16-38.1The range of Lesser Prairie-Chickens (Tympanuchus pallidicinctus) spans 4 unique ecoregions along 2 distinct environmental gradients. The Sand Shinnery Oak Prairie ecoregion of the Southern High Plains of New Mexico and Texas is environmentally isolated, warmer, and more arid than the Short-Grass, Sand Sagebrush, and Mixed-Grass Prairie ecoregions in Colorado, Kansas, Oklahoma, and the northeast panhandle of Texas. Weather is known to influence Lesser Prairie-Chicken nest survival in the Sand Shinnery Oak Prairie ecoregion; regional variation may also influence nest microclimate and, ultimately, survival during incubation. To address this question, we placed data loggers adjacent to nests during incubation to quantify temperature and humidity distribution functions in 3 ecoregions. We developed a suite of a priori nest survival models that incorporated derived microclimate parameters and visual obstruction as covariates in Program MARK. We monitored 49 nests in Mixed-Grass, 22 nests in Sand Shinnery Oak, and 30 nests in Short-Grass ecoregions from 2010 to 2014. Our findings indicated that (1) the Sand Shinnery Oak Prairie ecoregion was hotter and drier during incubation than the Mixed- and Short-Grass ecoregions; (2) nest microclimate varied among years within ecoregions; (3) visual obstruction was positively associated with nest survival; but (4) daily nest survival probability decreased by 10% every half-hour when temperature was greater than 34°C and vapor pressure deficit was less than - 23 mmHg during the day (about 0600-2100 hours). Our major finding confirmed microclimate thresholds for nest survival under natural conditions across the species' distribution, although Lesser Prairie-Chickens are more likely to experience microclimate conditions that result in nest failures in the Sand Shinnery Oak Prairie ecoregion. The species would benefit from identification of thermal landscapes and management actions that promote cooler, more humid nest microclimates. © 2016 Cooper Ornithological Society

Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer.

Genome-wide association studies (GWAS) and large-scale replication studies have identified common variants in 79 loci associated with breast cancer, explaining ∼14% of the familial risk of the disease. To identify new susceptibility loci, we performed a meta-analysis of 11 GWAS, comprising 15,748 breast cancer cases and 18,084 controls together with 46,785 cases and 42,892 controls from 41 studies genotyped on a 211,155-marker custom array (iCOGS). Analyses were restricted to women of European ancestry. We generated genotypes for more than 11 million SNPs by imputation using the 1000 Genomes Project reference panel, and we identified 15 new loci associated with breast cancer at P < 5 × 10(-8). Combining association analysis with ChIP-seq chromatin binding data in mammary cell lines and ChIA-PET chromatin interaction data from ENCODE, we identified likely target genes in two regions: SETBP1 at 18q12.3 and RNF115 and PDZK1 at 1q21.1. One association appears to be driven by an amino acid substitution encoded in EXO1.BCAC is funded by Cancer Research UK (C1287/A10118, C1287/A12014) and by the European Community's Seventh Framework Programme under grant agreement 223175 (HEALTH-F2-2009-223175) (COGS). Meetings of the BCAC have been funded by the European Union COST programme (BM0606). Genotyping on the iCOGS array was funded by the European Union (HEALTH-F2-2009-223175), Cancer Research UK (C1287/A10710, C8197/A16565), the Canadian Institutes of Health Research (CIHR) for the CIHR Team in Familial Risks of Breast Cancer program and the Ministry of Economic Development, Innovation and Export Trade of Quebec, grant PSR-SIIRI-701. Combination of the GWAS data was supported in part by the US National Institutes of Health (NIH) Cancer Post-Cancer GWAS initiative, grant 1 U19 CA148065-01 (DRIVE, part of the GAME-ON initiative). For a full description of funding and acknowledgments, see the Supplementary Note.This is the author accepted manuscript. The final version is available from NPG via http://dx.doi.org/10.1038/ng.324

Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease

BACKGROUND: Patients with atherosclerotic vascular disease remain at high risk for cardiovascular events despite effective statin-based treatment of low-density lipoprotein (LDL) cholesterol levels. The inhibition of cholesteryl ester transfer protein (CETP) by anacetrapib reduces LDL cholesterol levels and increases high-density lipoprotein (HDL) cholesterol levels. However, trials of other CETP inhibitors have shown neutral or adverse effects on cardiovascular outcomes. METHODS: We conducted a randomized, double-blind, placebo-controlled trial involving 30,449 adults with atherosclerotic vascular disease who were receiving intensive atorvastatin therapy and who had a mean LDL cholesterol level of 61 mg per deciliter (1.58 mmol per liter), a mean non-HDL cholesterol level of 92 mg per deciliter (2.38 mmol per liter), and a mean HDL cholesterol level of 40 mg per deciliter (1.03 mmol per liter). The patients were assigned to receive either 100 mg of anacetrapib once daily (15,225 patients) or matching placebo (15,224 patients). The primary outcome was the first major coronary event, a composite of coronary death, myocardial infarction, or coronary revascularization. RESULTS: During the median follow-up period of 4.1 years, the primary outcome occurred in significantly fewer patients in the anacetrapib group than in the placebo group (1640 of 15,225 patients [10.8%] vs. 1803 of 15,224 patients [11.8%]; rate ratio, 0.91; 95% confidence interval, 0.85 to 0.97; P=0.004). The relative difference in risk was similar across multiple prespecified subgroups. At the trial midpoint, the mean level of HDL cholesterol was higher by 43 mg per deciliter (1.12 mmol per liter) in the anacetrapib group than in the placebo group (a relative difference of 104%), and the mean level of non-HDL cholesterol was lower by 17 mg per deciliter (0.44 mmol per liter), a relative difference of -18%. There were no significant between-group differences in the risk of death, cancer, or other serious adverse events. CONCLUSIONS: Among patients with atherosclerotic vascular disease who were receiving intensive statin therapy, the use of anacetrapib resulted in a lower incidence of major coronary events than the use of placebo. (Funded by Merck and others; Current Controlled Trials number, ISRCTN48678192 ; ClinicalTrials.gov number, NCT01252953 ; and EudraCT number, 2010-023467-18 .)